Thrivent Financial For Lutherans grew its position in shares of MiMedx Group, Inc. (NASDAQ:MDXG) by 70.2% during the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 631,664 shares of the medical equipment provider’s stock after buying an additional 260,514 shares during the quarter. Thrivent Financial For Lutherans owned approximately 0.57% of MiMedx Group worth $7,965,000 as of its most recent filing with the Securities and Exchange Commission.
Other institutional investors have also recently modified their holdings of the company. Dimensional Fund Advisors LP lifted its position in shares of MiMedx Group by 2.4% during the second quarter. Dimensional Fund Advisors LP now owns 42,357 shares of the medical equipment provider’s stock worth $634,000 after purchasing an additional 982 shares in the last quarter. First Trust Advisors LP lifted its position in shares of MiMedx Group by 44.7% during the third quarter. First Trust Advisors LP now owns 162,318 shares of the medical equipment provider’s stock worth $1,928,000 after purchasing an additional 50,139 shares in the last quarter. Crossmark Global Holdings Inc. acquired a new position in MiMedx Group in the third quarter valued at approximately $594,000. Stevens Capital Management LP acquired a new position in MiMedx Group in the third quarter valued at approximately $160,000. Finally, American Century Companies Inc. lifted its holdings in MiMedx Group by 491.0% in the third quarter. American Century Companies Inc. now owns 559,122 shares of the medical equipment provider’s stock valued at $6,642,000 after buying an additional 464,509 shares during the period. 80.35% of the stock is currently owned by hedge funds and other institutional investors.
Several equities analysts recently weighed in on MDXG shares. Zacks Investment Research lowered shares of MiMedx Group from a “hold” rating to a “sell” rating in a report on Friday, December 8th. ValuEngine downgraded shares of MiMedx Group from a “hold” rating to a “sell” rating in a research note on Thursday, March 1st. Lake Street Capital set a $18.00 target price on shares of MiMedx Group and gave the company a “buy” rating in a research note on Thursday, December 14th. Needham & Company LLC downgraded shares of MiMedx Group from a “strong-buy” rating to a “hold” rating in a research report on Tuesday, February 20th. Finally, BidaskClub downgraded shares of MiMedx Group from a “buy” rating to a “hold” rating in a research report on Wednesday, February 21st. Four research analysts have rated the stock with a sell rating, two have given a hold rating and two have issued a buy rating to the company. The stock has a consensus rating of “Hold” and a consensus price target of $14.75.
Shares of MDXG stock opened at $6.46 on Friday. The firm has a market capitalization of $769.47, a price-to-earnings ratio of 53.83, a PEG ratio of 0.90 and a beta of 1.62. MiMedx Group, Inc. has a one year low of $6.05 and a one year high of $18.25.
MiMedx Group announced that its Board of Directors has approved a share repurchase plan on Wednesday, December 13th that permits the company to repurchase $10.00 million in shares. This repurchase authorization permits the medical equipment provider to buy shares of its stock through open market purchases. Stock repurchase plans are typically an indication that the company’s board of directors believes its stock is undervalued.
TRADEMARK VIOLATION NOTICE: “Thrivent Financial For Lutherans Boosts Stake in MiMedx Group, Inc. (MDXG)” was posted by Dispatch Tribunal and is the property of of Dispatch Tribunal. If you are accessing this piece on another website, it was illegally stolen and republished in violation of U.S. and international trademark and copyright law. The correct version of this piece can be read at https://www.dispatchtribunal.com/2018/04/07/mimedx-group-inc-mdxg-position-boosted-by-thrivent-financial-for-lutherans.html.
MiMedx Group Profile
MiMedx Group, Inc, a biopharmaceutical company, develops and markets regenerative biologics utilizing human placental tissue allografts with patent-protected processes for various sectors of healthcare. It processes the human placental tissue utilizing its proprietary PURION Process to produce allografts.
Receive News & Ratings for MiMedx Group Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for MiMedx Group and related companies with MarketBeat.com's FREE daily email newsletter.